Zoetis Announces Plans to Expand Operations in Lincoln
July 02 2013 - 9:00AM
Business Wire
Zoetis Inc. (NYSE: ZTS), formerly the animal health business
unit of Pfizer Inc., announced plans to expand its manufacturing
facility in Lincoln, Neb., to facilitate the production of
high-quality, reliable medicines for veterinarians, livestock
producers and the animals under their care. A world leader in
animal health, Zoetis expects this expansion to affirm its
longstanding commitment to being a world-class manufacturer of
animal health products as well as to continue to be an employer of
choice in Lincoln.
The plan calls for a 19,000 square-foot, three-story expansion
of the existing production facility to accommodate the transfer of
products from a third-party manufacturer to Lincoln. Early stages
of planning and construction have begun and groundbreaking is
expected to occur later this summer, initiating the start of the
full construction phase. Zoetis expects to complete construction in
2014.
This expansion will help ensure a reliable, consistent supply of
quality medicines for animals. Today, Zoetis produces some of its
flagship pharmaceutical products and vaccines at the Lincoln plant,
including Bovi-Shield Gold® and RespiSure One® for livestock and
Rimadyl® for dogs. The site is one of the largest internal
manufacturing operations within Zoetis, employing more than 500
people today; the facility expansion could create as many as 30 new
positions at peak production time.
“Zoetis is excited about the opportunity to expand its
manufacturing footprint in Lincoln and to leverage the expertise in
high-quality manufacturing that our colleagues have demonstrated in
Lincoln for decades,” said Michael Morgan, site leader in
Lincoln.
Zoetis and its predecessors have long held a presence in the
Lincoln area. In the early 20th century, drug firms and
distributors such as Norden Laboratories established facilities in
Nebraska that evolved over time. Since then, more recent
incarnations of these animal health companies, including the Zoetis
facility, have continued to serve as an important part of the
Lincoln community. The Lincoln facility is a key site in Zoetis’
global manufacturing network and one of the largest suppliers of
Zoetis’ animal health products for the world. It has been in
operation at its current location since 1961, producing 1,200
finished goods for more than 100 markets annually.
“This expansion shows our continuing commitment to the Lincoln
community, a community that we have been a part of for several
decades. We are proud of our new name, Zoetis, and look forward to
continuing to produce great quality medicines and vaccines for our
customers,” said Morgan.
About Zoetis
Zoetis (zō-EH-tis) is the leading animal health company,
dedicated to supporting its customers and their businesses.
Building on a 60-year history as the animal health business of
Pfizer, Zoetis discovers, develops, manufactures and markets
veterinary vaccines and medicines, with a focus on both farm and
companion animals. The company generated annual revenues of $4.3
billion in 2012. It has more than 9,300 employees worldwide and a
local presence in approximately 70 countries, including 29
manufacturing facilities in 11 countries. Its products serve
veterinarians, livestock producers and people who raise and care
for farm and companion animals in 120 countries. For more
information on the company, visit www.zoetis.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, which
reflect Zoetis’ current views with respect to business plans or
prospects, future operating or financial performance, and other
future events. These statements are not guarantees of future
performance. Forward-looking statements are subject to risks and
uncertainties. If one or more of these risks or uncertainties
materialize, or if management's underlying assumptions prove to be
incorrect, actual results may differ materially from those
contemplated by a forward-looking statement. Forward-looking
statements speak only as of the date on which they are made. Zoetis
expressly disclaims any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of
risks, uncertainties and other matters can be found in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2012,
including in the sections thereof captioned “Forward-Looking
Information and Factors That May Affect Future Results” and “Item
1A. Risk Factors”, and in our reports on Form 8-K. These filings
and subsequent filings are available online at www.sec.gov or on
request from Zoetis.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'Investors' section of our web site at www.zoetis.com, on our Facebook page at
http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage
investors and potential investors to consult our web site regularly
and to follow us on Facebook and Twitter for important information
about us.
Media:Zoetis Inc.Bill Price,
1-973-443-2742 (o)william.price@zoetis.comorElinore White,
1-973-443-2835 (o)elinore.y.white@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024